These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 2879156)
1. An investigation by the ABPI (Association of the British Pharmaceutical Industry). Wilmshurst P Lancet; 1987 Jan; 1(8524):104. PubMed ID: 2879156 [No Abstract] [Full Text] [Related]
2. Roche is suspended from ABPI for "actions likely to bring discredit" on the industry. Dobson R BMJ; 2008 Jul; 337(7662):a835. PubMed ID: 18632675 [No Abstract] [Full Text] [Related]
3. Government acts on gifts from drug companies. Beecham L BMJ; 1994 Jul; 309(6950):292. PubMed ID: 11644580 [No Abstract] [Full Text] [Related]
4. Fraud and misconduct in clinical research: is it prejudicial to patient safety? Wells F Adverse Drug React Acute Poisoning Rev; 1992; 11(4):241-55. PubMed ID: 11652183 [No Abstract] [Full Text] [Related]
5. Code of practice for the clinical assessment of licensed medicinal products in general practice. Br Med J (Clin Res Ed); 1983 Apr; 286(6373):1295-7. PubMed ID: 6404435 [TBL] [Abstract][Full Text] [Related]
6. Fraud in drug research. Brahams D Lancet; 1992 Aug; 340(8817):477-8. PubMed ID: 11643085 [No Abstract] [Full Text] [Related]
7. Post-marketing surveillance of adverse reactions to new medicines. Wilson AB Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357 [No Abstract] [Full Text] [Related]
8. PDA comments on draft guidance for industry on changes to an approved NDA or ANDA. Parenteral Drug Association. PDA J Pharm Sci Technol; 1999; 53(5):264-72. PubMed ID: 10754723 [No Abstract] [Full Text] [Related]
9. Voluntary control of drug promotion in Sweden. Perman E N Engl J Med; 1990 Aug; 323(9):616-7. PubMed ID: 2381456 [No Abstract] [Full Text] [Related]
10. Some further comments on aseptic processing guidance, or the fool on the hill: Parenteral Drug Association. Agalloco J PDA J Pharm Sci Technol; 2003; 57(5):324-30. PubMed ID: 14677624 [No Abstract] [Full Text] [Related]
11. Highlights of Good Manufacturing Practice in Japan. Morita K J Parenter Sci Technol; 1990; 44(1):35-8. PubMed ID: 2313491 [TBL] [Abstract][Full Text] [Related]
12. Drug compensation rules under attack. New Sci; 1983 Sep; 99(1374):669. PubMed ID: 11655565 [No Abstract] [Full Text] [Related]
13. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association. J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499 [No Abstract] [Full Text] [Related]
14. The ABPI code of practice: controls on the promotion of prescription medicines. Aitken P Clin Med (Lond); 2008 Apr; 8(2):128-9. PubMed ID: 18478851 [No Abstract] [Full Text] [Related]
15. Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. Herxheimer A; Collier J BMJ; 1990 Feb; 300(6720):307-11. PubMed ID: 2106963 [TBL] [Abstract][Full Text] [Related]
16. Supporting the industry: the Association of the British Pharmaceutical Industry. Trends Pharmacol Sci; 1996 Feb; 17(2):50. PubMed ID: 8929840 [No Abstract] [Full Text] [Related]
17. Drug industry's new code criticised for lacking teeth. Coombes R BMJ; 2005 Nov; 331(7527):1225. PubMed ID: 16308367 [No Abstract] [Full Text] [Related]
18. Carleton's corner. Should the United States pharmacopeia define manufacturing process limits? Korczynski MS J Parenter Sci Technol; 1991; 45(2):76. PubMed ID: 2051259 [No Abstract] [Full Text] [Related]
19. ASHP guidelines for selecting pharmaceutical manufacturers and suppliers. Am J Hosp Pharm; 1991 Mar; 48(3):523-4. PubMed ID: 2029002 [No Abstract] [Full Text] [Related]
20. Guidelines for pharmacists and the pharmaceutical industry. The Canadian Society of Hospital Pharmacists. Dimens Health Serv; 1990 Nov; 67(8):14-6. PubMed ID: 2276520 [No Abstract] [Full Text] [Related] [Next] [New Search]